Principal Financial Group Inc. Sells 9,604 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Principal Financial Group Inc. trimmed its position in shares of Standard BioTools Inc. (NASDAQ:LAB) by 29.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,493 shares of the company’s stock after selling 9,604 shares during the period. Principal Financial Group Inc.’s holdings in Standard BioTools were worth $43,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Geode Capital Management LLC boosted its holdings in Standard BioTools by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 6,949,717 shares of the company’s stock valued at $13,415,000 after purchasing an additional 154,848 shares during the period. Hollow Brook Wealth Management LLC bought a new position in Standard BioTools during the third quarter valued at about $10,679,000. State Street Corp raised its holdings in Standard BioTools by 26.7% in the 3rd quarter. State Street Corp now owns 5,495,136 shares of the company’s stock valued at $10,606,000 after acquiring an additional 1,157,984 shares in the last quarter. Barclays PLC lifted its position in shares of Standard BioTools by 13.2% in the 3rd quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock worth $6,231,000 after acquiring an additional 377,195 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Standard BioTools by 188.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock worth $4,719,000 after purchasing an additional 1,597,728 shares in the last quarter. 53.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, TD Cowen lowered their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a report on Thursday, October 31st.

Standard BioTools Trading Down 0.6 %

NASDAQ LAB opened at $1.76 on Wednesday. The stock’s 50 day moving average is $1.87 and its two-hundred day moving average is $1.90. The company has a market capitalization of $655.18 million, a price-to-earnings ratio of -2.48 and a beta of 1.61. Standard BioTools Inc. has a 1-year low of $1.21 and a 1-year high of $3.04.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.